These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 19949330)
1. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Hankey GJ Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Wu B; Kun L; Liu X; He B Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510 [TBL] [Abstract][Full Text] [Related]
4. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Shah H; Gondek K Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. Langkilde LK; Bergholdt Asmussen M; Overgaard M J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833 [TBL] [Abstract][Full Text] [Related]
8. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521 [TBL] [Abstract][Full Text] [Related]
9. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964 [TBL] [Abstract][Full Text] [Related]
10. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Schleinitz MD; Weiss JP; Owens DK Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Chang CH; Yang YH; Chen JH; Lin LJ Thromb Res; 2014 May; 133(5):782-9. PubMed ID: 24642004 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691 [TBL] [Abstract][Full Text] [Related]
14. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. Kirshner HS Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660 [TBL] [Abstract][Full Text] [Related]
16. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842 [TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Kourlaba G; Fragoulakis V; Maniadakis N Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. Lanitis T; Kongnakorn T; Jacobson L; De Geer A Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675 [TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. Wouters H; Thijs V; Annemans L J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]